These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12913831)

  • 1. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines.
    Rennels MB
    Semin Pediatr Infect Dis; 2003 Jul; 14(3):196-8. PubMed ID: 12913831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines.
    Rennels MB; Deloria MA; Pichichero ME; Losonsky GA; Englund JA; Meade BD; Anderson EL; Steinhoff MC; Edwards KM
    Pediatrics; 2000 Jan; 105(1):e12. PubMed ID: 10617749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extensive swelling of the limb and systemic symptoms after a fourth dose of acellular pertussis containing vaccines in England in children aged 3-6years.
    Southern J; Waight PA; Andrews N; Miller E
    Vaccine; 2017 Jan; 35(4):619-625. PubMed ID: 28017441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound examination of extensive limb swelling reactions after diphtheria-tetanus-acellular pertussis or reduced-antigen content diphtheria-tetanus-acellular pertussis immunization in preschool-aged children.
    Marshall HS; Gold MS; Gent R; Quinn PJ; Piotto L; Clarke MF; Roberton DM
    Pediatrics; 2006 Oct; 118(4):1501-9. PubMed ID: 17015541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose.
    Rennels MB; Black S; Woo EJ; Campbell S; Edwards KM
    Pediatr Infect Dis J; 2008 May; 27(5):464-5. PubMed ID: 18398385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 2000 Nov; 49(RR-13):1-8. PubMed ID: 11106289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.
    Scheifele DW; Halperin SA; Ochnio JJ; Ferguson AC; Skowronski DM
    Pediatr Infect Dis J; 2005 Dec; 24(12):1059-66. PubMed ID: 16371866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.
    Tozzi AE; Anemona A; Stefanelli P; Salmaso S; Ciofi degli Atti ML; Mastrantonio P; Giammanco A;
    Pediatrics; 2001 Feb; 107(2):E25. PubMed ID: 11158499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
    Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
    Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children.
    Kemmeren JM; Timmer SS; van der Maas NA; de Melker HE
    Vaccine; 2011 Jun; 29(26):4373-7. PubMed ID: 21514347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group.
    Liese JG; Stojanov S; Zink TH; Froeschle J; Klepadlo R; Kronwitter A; Harzer E; Jow S; Belohradsky BH
    Pediatr Infect Dis J; 2001 Oct; 20(10):981-8. PubMed ID: 11642633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation in a murine model of possible mechanisms of enhanced local reactions to post-primary diphtheria-tetanus toxoid boosters in recipients of acellular pertussis-diphtheria-tetanus vaccine.
    Ochiai M; Horiuchi Y; Yuen CT; Asokanathan C; Yamamoto A; Okada K; Kataoka M; Markey K; Corbel M; Xing D
    Hum Vaccin Immunother; 2014; 10(7):2074-80. PubMed ID: 25424818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Immune Response Among Children 4 Years of Age With Pronounced Local Adverse Events After the Fifth Diphtheria, Tetanus, Acellular Pertussis Vaccination.
    van der Lee S; Kemmeren JM; de Rond LGH; Öztürk K; Westerhof A; de Melker HE; Sanders EAM; Berbers GAM; van der Maas NAT; Rümke HC; Buisman AM
    Pediatr Infect Dis J; 2017 Sep; 36(9):e223-e229. PubMed ID: 28430750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.